Open AccessEfficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Author(s) -
Aurélien Marabelle,
Dung T. Le,
Paolo A. Ascierto,
Anna Maria Di Giacomo,
Ana De Jesus-Acosta,
Jean Pierre Delord,
Ravit Geva,
Maya Gottfried,
Nicolas Penel,
Shao Hui Huang,
Sarina A. Piha-Paul,
Toshihiko Doi,
Bo Gao,
Hyun Cheol Chung,
José A. López-Martín,
Yung Jue Bang,
Ronnie Shapira Frommer,
Manisha H. Shah,
Razi Ghori,
Andrew K. Joe,
Scott K. Pruitt,
Luis A. Díaz
Publication year - 2020
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.19.02105
Subject(s) - pembrolizumab , medicine , microsatellite instability , cancer , oncology , response evaluation criteria in solid tumors , clinical endpoint , dna mismatch repair , phases of clinical research , gastroenterology , immunotherapy , toxicity , clinical trial , colorectal cancer , allele , biochemistry , chemistry , microsatellite , gene
Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations that encode potential neoantigens. Such tumors are therefore likely to be immunogenic, triggering upregulation of immune checkpoint proteins. Pembrolizumab, an anti‒programmed death-1 monoclonal antibody, has antitumor activity against MSI-H/dMMR cancer. We report data from the phase II KEYNOTE-158 study of pembrolizumab in patients with previously treated, advanced noncolorectal MSI-H/dMMR cancer.